Option Fund
Dr. Lauren Silverman
is a Managing Director of the Novartis Option Fund
in Cambridge, MA, USA.
Prior to joining the Option Fund she was Global Head of Oncology Research Operations for Novartis. Previously, Lauren spent much of her career in Licensing & Business Development, first at OSI Pharmaceuticals and later at Pfizer with responsibilities in the areas of CNS, ophthalmology and oncology. Lauren was also a Director of Strategic Alliances and Head of Cell Biology where she led multiple research teams after having been a founding scientist of Cadus Pharmaceuticals. Lauren was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and Princeton University and earned her Ph.D. in molecular biology from the University of Utah. She is the author of multiple scientific publications and several issued patents and serves on the Business Advisory Board of the Epilepsy Research Foundation’s Epilepsy Therapy Project and National Cancer Institute’s SBIR review panel. Lauren currently serves on the Boards of Directors of Ascent Therapeutics, Proteostasis Therapeutics, Cequent Pharmaceuticals, Viamet Pharmaceuticals, and Pulmatrix Inc.
Portfolio Companies
Ascent Therapeutics Inc. (Board Seat)
Cequent Pharmaceuticals Inc. (Board Seat)
Proteostasis Therapeutics Inc. (Board Seat)
Pulmatrix, Inc. (Board Seat)
Viamet Pharmaceuticals (Board Seat)
